Smith & Nephew PLC

Smith & Nephew is a global medical devices business operating in the markets for advanced surgical devices comprising orthopaedic reconstruction and trauma, sports medicine and advanced wound management. Co.'s advanced medical products and services include: Orthopaedic Reconstruction and Trauma (joint replacement systems for knees and hips and products to help repair broken bones); Advanced Wound Management (treatment and prevention products for hard-to-heal wounds); and Sports Medicine (implants and enabling technologies for minimally invasive repair of the joint).
  • TickerSN.
  • ISINGB0009223206
  • ExchangeLondon Stock Exchange
  • SectorHealth Care Equipment & Services
  • CountryUnited Kingdom

Analysts

SMITH & NEPHEW PLC. sees an upgrade to Positive due to a better fundamental star rating

The general evaluation of SMITH & NEPHEW PLC. (GB), a company active in the Medical Equipment industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as defensive. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Positive. As of the analysis date August 16, 2019, the closing price was GBp 1,897.50 and its potential was estimated at GBp 1,992.38.

Nurhayati Wan

Smith & Nephew

Nurhayati Wan

Smith & Nephew

Nurhayati Wan

Smith & Nephew

1 director bought

A director at Smith & Nephew bought 2,380 shares at 1,674p and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board m...

Debbie Wang

Morningstar | Smith & Nephew Climbs the Value Chain Under New Management

While we continue to think Smith & Nephew faces key challenges in remaining an independent, mid-sized company in a medical technology world that has come to reward consolidation and scale, we like the steps new CEO Namal Nawana has taken to broaden the firm’s product portfolio into adjacent and complimentary markets. These additions do not necessarily widen Smith & Nephew’s narrow economic moat, but they help to reinforce the firm’s competitive position in advanced wound care, in our opinion. Our fair value estimate is unchanged. We like the addition of Osiris Therapeutics’ range of bone graf...

Debbie Wang

Smith & Nephew Climbs the Value Chain Under New Management

While we continue to think Smith & Nephew faces key challenges in remaining an independent, mid-sized company in a medical technology world that has come to reward consolidation and scale, we like the steps new CEO Namal Nawana has taken to broaden the firm’s product portfolio into adjacent and complimentary markets. These additions do not necessarily widen Smith & Nephew’s narrow economic moat, but they help to reinforce the firm’s competitive position in advanced wound care, in our opi...

Debbie Wang

Morningstar | Smith & Nephew Ventures into Regenerative Medicine with Latest Acquisition

Smith & Nephew's impressive innovation has allowed the company to carve out a slice of the orthopedic and wound-care markets. Though Smith & Nephew is smaller than the dominant orthopedic competitors, it has been a strong contributor in terms of introducing meaningful innovation with its pioneering hip resurfacing implant and knee replacements with Verilast technology, which the firm contends can last for 30 years. These are significant improvements that exceed the evolutionary innovation typically seen in orthopedics. Nevertheless, over the long term, we think the company's relatively small s...

Debbie Wang

Smith & Nephew Ventures into Regenerative Medicine with Latest Acquisition

Smith & Nephew finished up 2018 not materially far off from our projections and we’re leaving our fair value unchanged for now. Similar to previous quarters, large joint implants continued to lag market growth in the fourth quarter. Accounting for roughly one third of total revenue, quarterly knees and hips rose 3% on an underlying basis, which was then whittled down to 1% by foreign exchange headwinds. The main bright spots came in the form of sports medicine, the Navio hand-held orthopedic...

Debbie Wang

Morningstar | Smith & Nephew Prepares for More M&A Activity

Smith & Nephew finished up 2018 not materially far off from our projections and we’re leaving our fair value unchanged for now. Similar to previous quarters, large joint implants continued to lag market growth in the fourth quarter. Accounting for roughly one third of total revenue, quarterly knees and hips rose 3% on an underlying basis, which was then whittled down to 1% by foreign exchange headwinds. The main bright spots came in the form of sports medicine, the Navio hand-held orthopedic robot, and the Pico single-use negative pressure wound therapy device. Unfortunately, these products we...

1 director bought

A director at Smith & Nephew bought 2,380 shares at 1,674p and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board m...

SMITH & NEPHEW PLC. sees an upgrade to Positive due to a better fundamental star rating

The general evaluation of SMITH & NEPHEW PLC. (GB), a company active in the Medical Equipment industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as defensive. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Positive. As of the analysis date August 16, 2019, the closing price was GBp 1,897.50 and its potential was estimated at GBp 1,992.38.

Nurhayati Wan

Smith & Nephew

Nurhayati Wan

Smith & Nephew

Nurhayati Wan

Smith & Nephew

Nurhayati Wan

Smith & Nephew

MarketLine Department

Alliqua BioMedical, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Alliqua BioMedical, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Alliqua BioMedical, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive a...

MarketLine Department

Oculus Innovative Sciences, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Oculus Innovative Sciences, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Oculus Innovative Sciences, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain i...

Expert Corporate Governance Service (ECGS)

Smith & Nephew April 11th, 2019

Item 2: Approve the Remuneration Report The remuneration structure is unsatisfactory.  The main concern is that pay is not adequately weighted toward the long-term.  The structure is weighted more heavily towards short-term performance and alignment with performance has not been definitively demonstrated as qualitative criteria comprised 25% of the bonus and the committee had the discretion to make adjustments to the award. The committee also has the discretion to make bonus awards in the case of severance or change in control, which does not meet best practice.

Smith & Nephew – Proxinvest Corporate Governance Rating ® : B

Proxinvest Corporate Governance Rating ® helps investors integrate governance into their investment decision and identify governance risks and opportunities within their portfolio. Proxinvest Corporate Governance Rating ® Service rates European issuers through the analysis of four main themes : Ownership & Shareholder rights, Board & Committees, Audit & Process, Remuneration. Each theme is rated taking into account several comprehensive sub-categories. Our unique two-step process to achieve each rating includes a first step quantitative valuation and a second step qualitative filter...

Expert Corporate Governance Service (ECGS)

Proxy Report - 12/04/2018

Item 2: Approve the Remuneration Report. The structure is weighted more heavily towards short-term performance and alignment with performance has not been definitively demonstrated as qualitative criteria comprised 25% of the bonus and the committee had the discretion to make adjustments to the award.

Jérôme VINERIER

Analyse court terme - SMITH & NEPHEW PLC : La tendance de fond est clairement orientée à la hausse.

La tendance de fond est clairement orientée à la hausse. Les cours progressent encore, mais le mouvement montre moins de puissance. La prochaine résistance est à 1 342,00 p. La rupture du support à 1 150,00 p invaliderait cette tendance.

Jérôme VINERIER

Short term view - SMITH & NEPHEW PLC : The background trend is clearly bullish.

The background trend is clearly bullish. Prices are still making progress but there is less power in the movement. The next resistance is at 1,342.00 p. Breaking below the support at 1,150.00 p would invalidate the trend.

Jérôme VINERIER

Analyse court terme - SMITH & NEPHEW PLC : La tendance est baissière.

La tendance est baissière. Les prix baissent à nouveau, mais le mouvement est devenu hésitant. Le prochain support est à 1 251,00 p. La tendance baissière serait remise en cause au-dessus de 1 408,83 p.

Jérôme VINERIER

Short term view - SMITH & NEPHEW PLC : The trend is bearish.

The trend is bearish. Prices are falling again, but the movement has become hesitant. The next support is at 1,251.00 p. The bearish trend would be challenged above 1,408.83 p.

Jérôme VINERIER

Analyse moyen terme - SMITH & NEPHEW PLC : Les cours baissent.

La tendance est incertaine. Les cours baissent, et il y a une possibilité d'accélération baissière. Une nouvelle tendance baissière tente de démarrer.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch